FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/ — The U.S. Food and Drug…
Read More
FDA Approves Monoferric
FDA Approves Monoferric (ferric derisomaltose) Injection for the Treatment of Iron Deficiency Anemia MORRISTOWN, N.J., Jan. 29, 2020 /PRNewswire/ — Pharmacosmos Therapeutics Inc. is pleased to announce…
Read More
FDA panel: Expand use of fish oil drug Vascepa
Approved use of the prescription-strength fish oil drug Vascepa should be widened to include more patients at risk for heart attack and stroke, a U.S….
Read More
Risks of the new smoke: How harmful are E-cigarettes?
They look good. Cool. Technically. Smart somehow. E-cigarettes promise of easy pleasure without serious consequences, such as lung cancer. Because instead of burning tobacco, a…
Read More
FDA approves ruzurgi for children with rare autoimmune disorder
(HealthDay)—Ruzurgi (amifampridine) tablets are now approved to treat Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to 17 years, the U.S. Food and Drug Administration…
Read More
FDA orders label warning on alcohol use with ‘female viagra’
(HealthDay)—A drug touted as a “female Viagra” can cause severe low blood pressure and fainting when used with alcohol, the U.S. Food and Drug Administration…
Read More
FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
South San Francisco, CA — March 18, 2019 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the…
Read More
FDA allows treatment of depression with club drug’s cousin
A mind-altering medication related to the club drug Special K won U.S. approval Tuesday for patients with hard-to-treat depression, the first in a series of…
Read More
FDA chief threatens to halt E-cigarette sales
(HealthDay)—Sales of electronic cigarettes could be halted if companies do not stop marketing the devices to youth, U.S. Food and Drug Administration Commissioner Scott Gottlieb,…
Read More
FDA Approves Generic Latuda for Schizophrenia and Bipolar Depression
The cash price for a 30-day supply of brand-name Latuda is around $1,500. Lurasidone’s release could be a reprieve for patients struggling to afford Latuda….
Read More